IceCure Medical Ltd. (ICCM) stock
Close on Nov 11, 2026Market cap $2.54MP/E 0.1Yield –
IceCure Medical Ltd. grew revenue 2.7% to $3.38M over fiscal 2025. Free cash flow was -$14.61M. At the latest close the market valued the company at $2.54M, 0.1 times its earnings.
Key statistics
Valuation at the latest close; fundamentals over fiscal 2025, balances at Jun 30, 2026
Valuation
- Market cap
- $2.54M
- P/E ratio
- 0.1
- Price to sales
- 0.75
- Price to book
- 0.21
- Dividend yield
- –
- Free cash flow yield
- -574.53%
Fundamentals
- Revenue
- $3.38M
- Net income
- -$15.06M
- EPS, diluted
- $7.20
- Free cash flow
- -$14.61M
Trading
- Previous close
- $0.79
- Open
- $0.80
- Day's range
- $0.74 – $0.82
- Volume
- 122,080
- Average volume (20 days)
- 127,333
- Beta (5 years)
- 0.69
- 52-week range
- $0.65 – $22.50
- RSI (14 days)
- 27.9
- Volatility (1 year)
- 232.0%
- Relative volume
- 0.88×
- WACC
- 8.3%
Market cap history
Month-end market cap since 2020, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 11, 2026. The S&P 500 is measured by the SPY fund.
| Period | ICCM | S&P 500 | Difference | ICCM per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -32.5% | -2.4% | −30.1 pts | ||
| 3 months | -78.9% | -1.2% | −77.7 pts | ||
| Year to date | -95.9% | +12.3% | −108.2 pts | ||
| 1 year | -96.4% | +12.4% | −108.9 pts | ||
| 3 years | -96.8% | +78.8% | −175.6 pts | -68.2% | +21.4% |
| 5 years | -99.6% | +75.2% | −174.8 pts | -67.0% | +11.9% |
| 10 years | -87.6% | +311.1% | −398.7 pts | -18.9% | +15.2% |
Eight years at a glance
Fiscal years 2018 to 2025, USD
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases IceCure Medical filed with the SEC as exhibits to Form 8-K or 6-K
- 6-K
- 6-K
- 6-K
- 6-K
- 6-K
- 6-K
About IceCure Medical
Surgical & Medical Instruments & Apparatus
IceCure Medical Ltd. is an Israeli medical device company that researches, develops, and commercializes liquid-nitrogen-based cryoablation systems to destroy benign and malignant tumors through freezing. Its proprietary technology provides a minimally invasive alternative to surgery for tumors in the breast, lungs, kidneys, and bones. The company's lead commercial product is the ProSense system alongside its single-use disposable CryoProbes, while its pipeline includes next-generation systems such as the single-probe XSense and multi-probe MSense platforms. IceCure primarily markets its cryoablation products to healthcare providers, physicians, and hospitals treating low-risk breast cancer and other tumor indications.
Company profile, executives and historyIceCure Medical stock: common questions
What is IceCure Medical's stock price?
ICCM closed at $0.74 on Nov 11, 2026, down 6.06% on the day. Over the past 52 weeks it traded between $0.65 and $22.50.
What is IceCure Medical's market cap?
IceCure Medical was worth $2.54M at the close on Nov 11, 2026: the share price times the diluted shares outstanding.
What is ICCM's P/E ratio?
ICCM trades at 0.1 times earnings, based on diluted earnings per share of $7.20 over fiscal 2025.
How much revenue does IceCure Medical make?
IceCure Medical reported revenue of $3.38M for fiscal 2025, up 2.7% from a year earlier.
Does IceCure Medical pay a dividend?
No. IceCure Medical has not paid a cash dividend over the last twelve months.
How has ICCM stock performed over the past year?
Including dividends, ICCM returned -96.4% over the past year, against +12.4% for the S&P 500.
Who are IceCure Medical's competitors?
Companies most similar to IceCure Medical by business, industry and size include RNXT, PLSE, FEMY, INBS, PROF.
See a number that looks wrong?